Merck has entered into a definitive agreement to sell its Consumer Care business to Bayer AG for $14.2 billion. Bayer AG will acquire Merck’s existing OTC business, including the global trademark and prescription rights for Claritin and Afrin. The deal is expected to close in 2H14, subject to customary closing conditions.   The companies also entered clinical development collaboration to market and develop a portfolio of soluble guanylate cyclase (sGC) modulators, including Bayer’s Adempas (rioc...